title: Reply to O'Riordan et al.
authors.affiliation: 1Infectious Disease Clinical Outcomes Research Unit,Division of Infectious Disease,Los Angeles Biomedical Research Institute,Harbor-UCLA Medical Center,Torrance,California.
authors.forename: James A
authors.initials: JA
authors.lastname: McKinnell
authors.affiliation: 3Public Health Computational and Operations Research Group,Johns Hopkins Bloomberg School of Public Health,Baltimore,Maryland.
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Bartsch
authors.affiliation: 3Public Health Computational and Operations Research Group,Johns Hopkins Bloomberg School of Public Health,Baltimore,Maryland.
authors.forename: Bruce Y
authors.initials: BY
authors.lastname: Lee
authors.affiliation: 4Division of Infectious Diseases and Health Policy Research Institute,University of California,Irvine School of Medicine,Irvine,California.
authors.forename: Susan S
authors.initials: SS
authors.lastname: Huang
authors.affiliation: 1Infectious Disease Clinical Outcomes Research Unit,Division of Infectious Disease,Los Angeles Biomedical Research Institute,Harbor-UCLA Medical Center,Torrance,California.
authors.forename: Loren G
authors.initials: LG
authors.lastname: Miller
mesh_terms: D002353:Carrier State / Q000175:diagnosis*; D017721:Hospital Costs; D006801:Humans; D017053:Infection Control / Q000191:economics*; D008403:Mass Screening / Q000191:economics*; D055624:Methicillin-Resistant Staphylococcus aureus; D013203:Staphylococcal Infections / Q000175:diagnosis*